NCT06804499Recruiting
Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD). The main questions it aims to answer are: Are we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years? Participants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects. Medical healthcare records are used to follow all study subjects, and no follow-up visits are required.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 14 Jan 2025
- Start date
- 13 Jan 2025
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Tampere Heart Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT06804499
What you commit to
- Study type: Observational
- Planned participants: 4000
- From 13 Jan 2025 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.
- Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.
Other illness
- An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).
- A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \<23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).
Age
- Do-not-resuscitate (DNR) treatment decision
- Subgroup with blood samples:
- Blood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\>110ms in the latest ECG.
Other
- Life expectancy \<1 months.
- Intellectual disability or a significant disability affecting cognitive functions
Who the study is looking for
- Age \> 18 years
- A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).
- CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.
- An invasive coronary angiogram or CTA is done within three (3) months.
- Good or moderate everyday functional ability
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tampere University Hospital Tampere Heart Centre Coordinator of this site? Confirm its status | Tampere | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.